Related Experiment Video
Updated: Apr 19, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Predictors of metabolic dysfunction-associated steatotic liver diseases (MASLD) in Vietnamese population
Anh Gia Pham1,2, An Vu-Khanh Le3, Yen Thi-Hai Pham4,5
1Department of Oncology, Viet-Duc University Hospital, Hanoi, Vietnam. phamgiaanh@gmail.com.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises a spectrum of liver diseases from simple steatosis, metabolic dysfunction-associated steatohepatitis (MASH) which progresses to fibrosis and compensated cirrhosis. Worldwide, MASLD significantly contributes to the rising incidence of liver cancer. Lille is known about its predictors in Asian population and particularly among Vietnamese. We determined the predictors of MASLD in Vietnamese population using a hospital-based case-control study of 100 MASLD patients and 119 healthy controls. Unconditional logistic regression model was used to calculate odds ratios (ORs) and respective 95% confidence intervals (CIs) for MASLD in relation to potential predictors. Overall, body mass index (BMI) (OR> 23 vs. ≤23 kg/m2=1.93, 95% CI: 1.00-3.72), diabetes (OR = 4.46, 95% CI: 1.16-17.12); AST (OR≥40 vs. <40=4.18, 95% CI: 1.54-11.33), GGT (OR≥55738 vs. <55738=5.20, 95% CI: 2.39-11.33), and international normalized ratio (INR) (OR> 1.0 vs. ≤1.0=2.18, 95% CI: 1.15-4.14) were the predictors for MASLD. Other important clinical factors, including cardiometabolic condition, platelet, ALT, albumin, cholesterol or triglyceride were not associated with risk of MASLD. Clinical factors, including BMI, diabetes, AST, GGT, and INR played important roles as predictors for MASLD in Vietnamese population. Our findings, for the first time, provided evidence for risk stratification and treatment management of MASLD in Vietnamese population.
More Related Videos
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Related Concept Videos
Type II Diabetes I: Introduction
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Chronic Pancreatitis II: Pathophysiology
Type II Diabetes II: Pathophysiology